Rock Creek Adds Robert Scannell to Board

11/19/15

Rock Creek Pharmaceuticals, Inc., (OTCQB: RCPI), a clinical stage drug development company focused on the application of its lead compound being developed to treat chronic inflammatory conditions, announced today that the Company has made a key independent appointment to the Company’s Board of Directors with the recent election of Mr. Robert Scannell (Age 57), as a new director, bringing the number of directors to five.

Michael Mullan, MBBS, PhD, Chairman and CEO of Rock Creek Pharmaceuticals, said, “I am delighted that Bob is joining our Company as we advance through formal drug development. Bob’s experience, judgment and overall investment acumen, coupled with his long term support of the Company, will be extremely helpful as we work to expand our industry profile and corporate development.”

Mr. Scannell is a professional private equity investor, portfolio manager and investment management firm founder. He is the Co-Founder and General Partner of IASO Advisors, LLC, an investment firm focused on healthcare and biotech. Prior to IASO Advisors, Mr. Scannell was Founder and General Partner of Tradewinds Investment Management, accumulating a 20-year record of success and $400 million of assets. Mr. Scannell began his financial career working with corporate and convertible bonds, high yield and emerging market debt at Merrill Lynch Capital Markets. Mr. Scannell has a Juris Doctorate from Concord Law School, Los Angeles, CA., an MBA in Finance and a BA in Speech and Journalism, both from Penn State University. Mr. Scannell is a Chartered Financial Analyst (CFA).

About Anatabine Citrate:

Rock Creek Pharmaceuticals’ compound is a small molecule, cholinergic agonist that exhibits anti-inflammatory pharmacological characteristics, distinct from other anti-inflammatory drugs available such as biologics, steroids and non-steroidal anti-inflammatories. The Company’s lead compound has been investigated extensively in pre-clinical (in vitro and in vivo) studies resulting in several peer reviewed and published scientific journal articles, covering models of multiple sclerosis, Alzheimer’s disease, and autoimmune thyroiditis. All these studies demonstrated the anti-inflammatory effects of the Company’s compound. In addition, the Company’s compilation of human exposure, safety and tolerability data, has provided important insights for ongoing clinical and regulatory pharmaceutical development.

About Rock Creek Pharmaceuticals, Inc.:

Rock Creek Pharmaceuticals, Inc. is an emerging drug development company focused on the discovery, development and commercialization of new drugs, formulations and compounds that provide therapies for chronic and acute inflammatory diseases.

For more information, visit: http://www.rockcreekpharmaceuticals.com

It's on us. Share your news here.

Submit your stories and articles to citybizlist today.